Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ESRRA | P11474 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.34 |
| ▸ | FADS1 | O60427 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11514961 | 1.00 | ALDH1A1 (0.38) | ALDH1A1KDM4EHSD17B10PTGS2CFTR | |
| SCHEMBL27304888 | 0.83 | ALDH1A1 (0.40) | ALDH1A1KDM4EHSD17B10PTGS2CFTR | |
| SCHEMBL30338418 | 0.82 | PTGS2 (0.52) | ALDH1A1KDM4EHSD17B10PTGS2CYP3A4 | |
| SCHEMBL288752 | 0.82 | PTGS2 (0.52) | ALDH1A1KDM4EHSD17B10PTGS2CYP3A4 | |
| SCHEMBL59839 | 0.82 | PTGS2 (0.52) | ALDH1A1KDM4EHSD17B10PTGS2CYP3A4 | |
| SCHEMBL5215577 | 0.82 | PTGS2 (0.52) | ALDH1A1KDM4EHSD17B10PTGS2CYP3A4 | |
| SCHEMBL250282 | 0.82 | CXCL8 (0.49) | ALDH1A1KDM4EHSD17B10PTGS2CFTR | |
| SCHEMBL8203180 | 0.82 | PTGS2 (0.42) | ALDH1A1KDM4EHSD17B10PTGS2CFTR | |
| SCHEMBL14505423 | 0.80 | ALDH1A1 (0.38) | ALDH1A1KDM4EHSD17B10PTGS2CFTR | |
| SCHEMBL11723567 | 0.78 | CA2 (0.37) | ALDH1A1KDM4EHSD17B10PTGS2CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6875877-B2 | Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides | LI JINGLIN JAMES T (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1331225-A1 | Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides | G.D. SEARLE & CO. (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-1042314-B1 | METHOD OF PREPARING ENANTIOMERICALLY-ENRICHED TETRAHYDROBENZOTHIEPINE OXIDES | SEARLE & CO (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20020188119-A1 | Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides | LI JINGLIN (US) | 2002-12-12 | — | — | US | disclosed |
| US-6369220-B1 | OXIDIZING AN ARYL-3-HYDROXYPROPYLSULFIDE; OXIDIZING 3-HYDROXY GROUP INTO ARYL-3-PROPANALSULFOXIDE; CYCLIZATION | G.D. SEARLE, LLC | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188119-A1 | Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides | TST, THOP1, TH | ALDH1A1 767/4885KDM4E 2499/4885HSD17B10 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.